Discover

MXCT
MaxCyte, Inc.
1.22
22 x 0.91
18 x 1.57
bid
ask
-
0.01
1.21%
12:12 PM
timesize
Ytd-21.61%
1y-45.75%
1.21
day range
1.27
0.64
52 week range
2.37
Open1.25Prev Close1.23Low1.21High1.27Mkt Cap130.15M
Vol327.99KAvg Vol1.15MEPS-0.36P/EN/AForward P/E-10.41
Beta1.16Short Ratio4.08Inst. Own70.20%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1250-d Avg1.05200-d Avg1.201yr Est8.67

MXCT News

VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering
businesswire.com
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering

ROCKVILLE, Md. & CHICAGO--(BUSINESS WIRE)-- #BioTechNews--VectorBuilder, a global leader in gene del

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED)
benzinga.com
Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— N

(Editor’s note: The future prices of benchmark tracking ETFs, and the headline, the lede and the eco

Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday
benzinga.com
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday

US stock futures mixed, Cisco and MaxCyte report positive earnings, Alibaba and Vishay to release re

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
seekingalpha.com
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte Q1 Earnings Call Highlights
marketbeat.com
MaxCyte Q1 Earnings Call Highlights

MaxCyte NASDAQ: MXCT reported lower first-quarter revenue compared with the prior year, as managemen

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Es

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $30.829M Est

MaxCyte (NASDAQ:MXCT) affirms FY2026 sales outlook from $30.000 million-$32.000 million to $30.000 m

benzinga.com
MaxCyte Q1 EPS $(0.04) Beats $(0.07) Estimate, Sales $9.651M Beat $7.298M Estimate

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.04) per share which beat the analyst consensu

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
globenewswire.com
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 mi

Earnings Scheduled For May 12, 2026
benzinga.com
Earnings Scheduled For May 12, 2026

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
globenewswire.com
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-en

MaxCyte, Inc. (NASDAQ:MXCT) Receives $5.50 Average Price Target from Analysts
defenseworld.net
MaxCyte, Inc. (NASDAQ:MXCT) Receives $5.50 Average Price Target from Analysts

MaxCyte, Inc. (NASDAQ: MXCT - Get Free Report) has been assigned a consensus rating of "Hold" from t

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engi

MaxCyte Q4 Earnings Call Highlights
defenseworld.net
MaxCyte Q4 Earnings Call Highlights

MaxCyte (NASDAQ: MXCT) executives told investors the company made "meaningful progress" in 2025 desp

benzinga.com
Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5

Craig-Hallum analyst Matt Hewitt maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript
seekingalpha.com
MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates
zacks.com
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Es

benzinga.com
MaxCyte Q4 EPS $(0.09), Inline, Sales $7.300M Miss $9.398M Estimate

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.09) per share which met the analyst consensus

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
globenewswire.com
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guid

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary an

Earnings Scheduled For March 24, 2026
benzinga.com
Earnings Scheduled For March 24, 2026

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
globenewswire.com
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engi

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
globenewswire.com
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-eng

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
globenewswire.com
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-eng

benzinga.com
MaxCyte Reports Q4 Revenue Around $6.7M Vs $9.3M Est, Full-Year Revenue Near $30M Vs $35.41M Est

MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing ena

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leadi

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
businesswire.com
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufac

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript
seekingalpha.com
MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

MaxCyte, Inc. ( MXCT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Mahe

benzinga.com
MaxCyte CFO Douglas Swirsky To Transition From Role In H1 2026

MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platfo

benzinga.com
MaxCyte Affirms FY2025 Sales Guidance of $29.261M-$32.512M vs $36.402M Est

MaxCyte (NASDAQ:MXCT) affirms FY2025 sales outlook from $29.261 million-$32.512 million to $29.261 m

benzinga.com
MaxCyte Q3 EPS $(0.12) Misses $(0.11) Estimate, Sales $6.829M Miss $8.370M Estimate

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consen

MaxCyte Announces Planned CFO Transition in 2026
globenewswire.com
MaxCyte Announces Planned CFO Transition in 2026

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-en

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
globenewswire.com
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-eng

Earnings Scheduled For November 12, 2025
benzinga.com
Earnings Scheduled For November 12, 2025

Insights into MaxCyte's Upcoming Earnings
benzinga.com
Insights into MaxCyte's Upcoming Earnings

benzinga.com
MaxCyte Reports Preliminary Q3 Revenue of $6.8M And Reiterates Its 2025 Revenue Guidance

MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platf

Earnings Scheduled For November 5, 2025
benzinga.com
Earnings Scheduled For November 5, 2025

benzinga.com
MaxCyte Signs Strategic Platform License Agreement With Moonlight Bio To Advance T Cell Therapy Deve

MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technolo

benzinga.com
MaxCyte Restructures Operations, Reduces Global Workforce By 34% To Unlock ~$13.6M In Annual Savings

MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platfor

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
benzinga.com
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga.com
MaxCyte Q2 EPS $(0.12) Misses $(0.10) Estimate, Sales $8.51M Miss $9.57M Estimate

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consen

benzinga.com
Earnings Scheduled For August 6, 2025

benzinga.com
MaxCyte Signs Licensing Deal With Adicet Bio To Support Development Of Gene-Edited Gamma Delta T Cel

MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet

benzinga.com
Stephens & Co. Assumes MaxCyte at Overweight, Announces Price Target of $6

Stephens & Co. analyst Helfey Hannah assumes MaxCyte (NASDAQ:MXCT) with a Overweight rating a

benzinga.com
MaxCyte Affirms FY2025 Sales Guidance of $35.11M-$37.39M vs $41.30M Est

MaxCyte (NASDAQ:MXCT) affirms FY2025 sales outlook from $35.11 million-$37.39 million to $35.11 mill

benzinga.com
MaxCyte Q1 EPS $(0.10) Beats $(0.11) Estimate, Sales $10.39M Beat $9.06M Estimate

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.10) per share which beat the analyst consensu

benzinga.com
Earnings Scheduled For May 7, 2025

benzinga.com
A Look at MaxCyte's Upcoming Earnings Report